Skip to content

US · PLUR · BIOTECHNOLOGY

Pluri Inc. (PLUR) intrinsic value and stock valuation

$0.94as of 2026-11-21 · Mkt cap 15.65M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pluri Inc. DCF and intrinsic value

InvestorsCraft values PLUR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PLUR’s statements →

Pluri Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Haifa, HA 3508409 pluri-biotech.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.34M+131.9% 5y CAGRd
20112025
Net income
-$-22.58M
20112025
Free cash flow
-$-19.83M
20112025
Total equity
-$-860K
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.34M$330K$290K$230K$0.00
Operating income-$-22.18M-$-22.16M-$-27.25M-$-41.59M-$-50.62M
Net income-$-22.58M-$-20.89M-$-28.32M-$-41.24M-$-49.87M
EPSd-$-3.56M-$-3.99M-$-6.18M-$-10.26M-$-14.21M
Operating cash flow-$-18.21M-$-18.02M-$-22.86M-$-36.5M-$-30.91M
Capital expenditure-$-1.62M-$-320K-$-260K-$-280K-$-370K
Free cash flow-$-19.83M-$-18.34M-$-23.12M-$-36.78M-$-31.28M
Total assets$38.7M$39.5M$50.8M$68.1M$93.5M
Total debt$34.1M$29.6M$29.9M$28.8M$24.6M
Net debt$28.2M$22.8M$24.6M$19M-$-6.66M
Total equity-$-860K$5.42M$15.3M$32.2M$57.2M
Cash and short-term investments$20.6M$30M$40.2M$55M$65M
Income statement
20252024202320222021
Revenue$1.34M$330K$290K$230K$0.00
Cost of revenue$680K$0.00$10K$1.05M$1.37M
Gross profit$650K$320K$280K-$-820K-$-1.37M
Research and development expenses$12.9M$12.5M$15.7M$24.4M$30.1M
Selling, general and administrative expenses$9.98M$10M$11.8M$17.5M$20.6M
Other expenses$0.00$0.00$0.00-$-1.05M-$-1.37M
Operating expenses$22.8M$22.5M$27.5M$40.8M$49.3M
Cost and expenses$23.5M$22.5M$27.5M$41.8M$50.6M
Interest income$1.14M$1.31M$1.08M$580K$490K
Interest expense$870K$870K$840K$890K$80K
Depreciation and amortization$320K$250K$360K$1.05M$1.37M
Ebitda-$-22.07M-$-20.23M-$-27.68M-$-39.43M-$-48.42M
Operating income-$-22.18M-$-22.16M-$-27.25M-$-41.59M-$-50.62M
Total other income/expenses, net-$-1.08M$810K-$-1.64M$220K$760K
Income before tax-$-23.25M-$-21.34M-$-28.89M-$-41.37M-$-49.87M
Income tax expense-$-10K$0.00$0.00$0.00$0.00
Net income-$-22.58M-$-20.89M-$-28.32M-$-41.24M-$-49.87M
Weighted average shares outstanding$6.34M$5.24M$4.58M$4.02M$3.51M
Weighted average diluted shares outstanding$6.34M$5.24M$4.58M$4.02M$3.51M
Balance sheet
20252024202320222021
Cash and short-term investments$20.6M$30M$40.2M$55M$65M
Net receivables$720K$640K$530K$1.32M$1.49M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$22.1M$31.1M$41.4M$57.8M$67.4M
Property, plant and equipment, net$8.72M$7.25M$8.32M$9.01M$2.23M
Goodwill and intangible assets$5.93M$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$16.6M$8.42M$9.39M$10.3M$26.2M
Total assets$38.7M$39.5M$50.8M$68.1M$93.5M
Accounts payable$870K$960K$1.81M$1.78M$2.53M
Short-term debt$28M$560K$630K$620K$630K
Deferred revenue$340K$120K$150K$110K$40K
Total current liabilities$32.3M$4.45M$5.62M$6.83M$11.5M
Long-term debt$6.1M$29.1M$29.3M$28.2M$24M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$7.22M$29.7M$29.9M$29.1M$24.9M
Capital lease obligations$6.76M$5.58M$6.38M$7.12M$730K
Total liabilities$39.6M$34.1M$35.5M$35.9M$36.4M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-443.06M-$-420.47M-$-399.58M-$-371.26M-$-330.02M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-860K$5.42M$15.3M$32.2M$57.2M
Total investments$14.7M$23.2M$34.8M$45.2M$33.7M
Total debt$34.1M$29.6M$29.9M$28.8M$24.6M
Net debt$28.2M$22.8M$24.6M$19M-$-6.66M
Cash flow statement
20252024202320222021
Net income-$-23.25M-$-21.34M-$-28.89M-$-41.37M-$-49.87M
Depreciation and amortization$320K$250K$360K$1.05M$1.37M
Stock-based compensation$2.14M$2.62M$3.98M$8.91M$14M
Change in working capital$4.19M-$-20K$1.69M-$-5.09M$3.53M
Accounts receivable-$-110K$440K-$-340K-$-330K-$-260K
Inventory$0.00$0.00$340K$330K$0.00
Accounts payable-$-230K-$-780K-$-20K-$-760K$580K
Net cash provided by operating activities-$-18.21M-$-18.02M-$-22.86M-$-36.5M-$-30.91M
Investments in property, plant and equipment-$-1.62M-$-320K-$-260K-$-280K-$-370K
Acquisitions, net$370K$0.00$0.00$0.00$0.00
Net cash used for investing activities$8.03M$10.6M$9.7M$11.8M-$-7.26M
Common stock issued$9.58M$90K$8.02M$0.00$36.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.53M$8.84M$8.02M$7.5M$61.4M
Net change in cash-$-470K$1.42M-$-5.16M-$-20.43M$22.6M
Cash at end of period$7.2M$7.67M$6.26M$11.4M$31.8M
Operating cash flow-$-18.21M-$-18.02M-$-22.86M-$-36.5M-$-30.91M
Capital expenditure-$-1.62M-$-320K-$-260K-$-280K-$-370K
Free cash flow-$-19.83M-$-18.34M-$-23.12M-$-36.78M-$-31.28M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pluri Inc.

        Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.

        CEO
        Yaacov Yanay
        Employees
        127
        Beta
        0.63

        Explore

        Frequently asked questions

        What is the intrinsic value of Pluri Inc. (PLUR)?

        InvestorsCraft does not currently publish an intrinsic value for PLUR. How the IC value is calculated.

        Is PLUR undervalued?

        InvestorsCraft does not publish an undervaluation signal for PLUR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.